Abstract | INTRODUCTION: METHODS: FUSCHAV patients (n = 120), divided into four groups according to AH and VH symptom severity (severe AHs combined with severe VHs [FUSCHSASV, 20 patients]; middle-to-moderate AHs combined with severe VHs [FUSCHMASV, 23 patients]; severe AHs combined with middle-to-moderate VHs [FUSCHSAMV, 28 patients]; and middle-to-moderate AHs combined with middle-to-moderate VHs [FUSCHMAMV, 26 patients]), were compared to healthy controls (n = 30). Gray matter volume (GMV) was adopted for brain structural alteration assessment. Total retinal thickness was adopted as a measure of retinal thickness impairment. RESULTS: In the pilot study, the rate of GMV reduction showed an inverted U-shaped pattern across the different FUSCHAV patient groups according to AH and VH severity. The degree of retinal impairment remained stable across the groups. More notably, in the secondary follow-up study, we observed that, after 6 months of treatment with antipsychotic agents, all the GMV reduction-related differences across the different patient groups disappeared, and both GMV and retinal thickness demonstrated a tendency to deteriorate. CONCLUSIONS: These findings indicate the need for heightened alertness on brain and retinal impairments in patients with FUSCHAV. Further deteriorations induced by antipsychotic agent treatment should be monitored in clinical practice.
|
Authors | Chuanjun Zhuo, Bo Xiao, Ce Chen, Deguo Jiang, Gongying Li, Xiaoyan Ma, Ranli Li, Lina Wang, Yong Xu, Chunhua Zhou, Xiaodong Lin |
Journal | Brain and behavior
(Brain Behav)
Vol. 10
Issue 6
Pg. e01611
(06 2020)
ISSN: 2162-3279 [Electronic] United States |
PMID | 32285647
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. |
Chemical References |
|
Topics |
- Antipsychotic Agents
(adverse effects)
- Brain
(diagnostic imaging)
- Follow-Up Studies
- Hallucinations
(drug therapy)
- Humans
- Pilot Projects
- Schizophrenia
(complications, drug therapy)
|